These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 38964315)
1. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315 [TBL] [Abstract][Full Text] [Related]
2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451 [TBL] [Abstract][Full Text] [Related]
3. An Organoid-Based Preclinical Model of Human Gastric Cancer. Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949 [TBL] [Abstract][Full Text] [Related]
4. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response. Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064 [TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer. Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669 [TBL] [Abstract][Full Text] [Related]
6. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application. Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861 [TBL] [Abstract][Full Text] [Related]
7. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073 [TBL] [Abstract][Full Text] [Related]
8. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617 [TBL] [Abstract][Full Text] [Related]
9. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Pamarthy S; Sabaawy HE Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953 [TBL] [Abstract][Full Text] [Related]
10. Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine. Yang R; Qi Y; Kwan W; Du Y; Yan R; Zang L; Yao X; Li C; Zhu Z; Zhang X; Gao H; Cheong IH; Kozlakidis Z; Yu Y J Transl Med; 2024 Aug; 22(1):754. PubMed ID: 39135062 [TBL] [Abstract][Full Text] [Related]
11. In vitro drug testing using patient-derived ovarian cancer organoids. Chen LY; Chou YT; Liew PL; Chu LH; Wen KC; Lin SF; Weng YC; Wang HC; Su PH; Lai HC J Ovarian Res; 2024 Oct; 17(1):194. PubMed ID: 39358778 [TBL] [Abstract][Full Text] [Related]
12. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484 [TBL] [Abstract][Full Text] [Related]
13. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411 [TBL] [Abstract][Full Text] [Related]
14. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. Ukai S; Honma R; Sakamoto N; Yamamoto Y; Pham QT; Harada K; Takashima T; Taniyama D; Asai R; Fukada K; Naka K; Tanabe K; Ohdan H; Yasui W Oncogene; 2020 Dec; 39(50):7265-7278. PubMed ID: 33046798 [TBL] [Abstract][Full Text] [Related]
15. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706 [TBL] [Abstract][Full Text] [Related]
16. Gastric cancer patient-derived organoids model for the therapeutic drug screening. Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703 [TBL] [Abstract][Full Text] [Related]
17. Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer. Wang L; Li PF; Geng M; Cao YC; Yin YC Diagn Pathol; 2013 Feb; 8():33. PubMed ID: 23432846 [TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029 [TBL] [Abstract][Full Text] [Related]
19. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643 [TBL] [Abstract][Full Text] [Related]
20. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]